DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Companion Diagnostics Market

Global Companion Diagnostics Market Opportunities and Forecast 2020-2027

  • DLR2526
  • 18 August, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Companion Diagnostics Market, By Product & Service (Assay kits & Reagents, Software & Services), By Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), Others), By Indication (Cardiovascular, Neurological Diseases, Cancer [Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gastric Cancer], Infectious Diseases, Others), By End User (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Others), and opportunities and forecast 2020-2027

Companion Diagnostics Market Overview

A companion diagnostic is a medical device, often an in vitro device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. The test helps a health care professional determine whether a particular therapeutic product’s benefits to patients will outweigh any potentially serious side effects or risks.
 
Several factors significantly boosting the growth of the global Companion Diagnostics market such as advantages of companion diagnostics, the increasing need for targeted therapy, the rising importance of personalized medicine, and the ever-increasing application areas of companion diagnostics. Additionally, other important factors such as increasing demand for next-generation sequencing, the rising importance of companion diagnostics in drug development, and a large number of clinical trials are further propelling the growth of this market progressively.
 
Furthermore, the companion diagnostics market is anticipated to experience noteworthy growth throughout the forecast period due to growth in R&D of targeted therapies, the discovery of new biomarkers for numerous conditions, and a large number of unmet needs for the treatment of cancer are majorly escalating the growth of the global Companion Diagnostics market.
 
On the downside, poor reimbursement policies, and longer developmental and approval phases are factors that are hampering the growth of the Companion Diagnostics Market.
 
Covid-19 Impact on Companion Diagnostics Market
 
In addition, the current Companion Diagnostics Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Companion Diagnostics Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
 
Companion Diagnostics Market Segment Overview
 
Based on the Technology, the Polymerase Chain Reaction (PCR) segment has the largest share of the global Companion Diagnostics market.  The large share of this segment can be primarily attributed to the easy use and extensive availability of PCR kits & reagents in companion diagnostic testing. In addition, other factors such as rising applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes and high turnaround time of PCR as compared to other technologies are further support to the growth of this segment.
 
By End User, the Pharmaceutical & Biopharmaceutical Companies is an important segment in the market. This is because of the widespread usage of companion diagnostics in these industries due to their increasing prominence in drug development and the rising importance of companion diagnostic biomarkers. In addition to this, the escalating demand for personalized medicine as well as the huge demand for targeted therapies for several diseases and disorders are also projected to boost the demand and acceptance of companion diagnostics among pharmaceutical & biopharmaceutical companies.
 
Companion Diagnostics Market, By Product & Service

·       Assay kits & Reagents
·       Software & Services
 
Companion Diagnostics Market, By Technology

·       Polymerase Chain Reaction (PCR) 
·       In Situ Hybridization (ISH) 
·       Next-Generation Sequencing (NGS)
·       Immunohistochemistry (IHC) 
·       Others
 
Companion Diagnostics Market, By Indication
  • Cardiovascular
  • Neurological Diseases
  • Cancer
    • Breast Cancer 
    • Lung Cancer 
    • Colorectal Cancer 
    • Melanoma 
    • Gastric Cancer 
  • Infectious Diseases 
  • Others
Companion Diagnostics Market, By End User

·       Pharmaceutical & Biopharmaceutical Companies
·       Reference Laboratories
·       CROs
·       Others

Companion Diagnostics Market Regional Overview

In terms of region, North America is expected to dominate the global Companion Diagnostics Market. This is because of the rising incidence of cancer, increasing health care expenditure, and rising demand for personalized treatment in this region. Similarly, the companion diagnostics market in the Asia Pacific is anticipated to grow at a significant rate over the forecast period. The growth of the market in this region is mainly attributed to the increasing prevalence of cancer, remarkable growth in research funding, and rise in proteomics & genomics research. Moreover, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in many APAC countries are anticipated to propel the growth of the Asia Pacific market.
 
Companion Diagnostics Market, By Geography
 
·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Companion Diagnostics Market Competitor overview

Some key developments and strategies adopted by manufacturers in Companion Diagnostics are highlighted below.

·       In August 2021, Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel as a companion diagnostic for TEPMETKO® a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020. TEPMETKO (tepotinib) is approved for use in patients with unresectable, advanced or recurrent non-small cell lung cancer with MET gene exon 14 skipping alterations.

·       In August 2021, QIAGEN and OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, announced signing a master companion diagnostics (CDx) agreement to develop a NGS CDx for OncXerna’s product candidate, Navicixizumab, and a non-exclusive license to the Xerna™ TME panel.

Companion Diagnostics Market, Key Players

·       F. Hoffmann-La Roche AG
·       Agilent Technologies, Inc.
·       QIAGEN N.V. 
·       Abbott Laboratories, Inc.
·       Almac Group
·       Danaher Corporation 
·       Illumina, Inc.
·       bioMérieux SA (France),
·       Myriad Genetics, Inc.,
·       Sysmex Corporation 
·       Thermo Fisher Scientific Inc.
·       Abnova Corporation
·       Guardant Health, Inc. 
·       Icon Plc
·       Biogenex Laboratories, Inc.

Companion Diagnostics Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Companion Diagnostics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Product & Service
        • 5.2.1. Assay kits & Reagents
        • 5.2.2. Software & Services
      • 5.3. Market Analysis, Insights and Forecast – By Technology
        • 5.3.1. Polymerase Chain Reaction (PCR)
        • 5.3.2. In Situ Hybridization (ISH)
        • 5.3.3. Next-Generation Sequencing (NGS)
        • 5.3.4. Immunohistochemistry (IHC)
        • 5.3.5. Others
      • 5.4. Market Analysis, Insights and Forecast – By Indication
        • 5.4.1. Cardiovascular
        • 5.4.2. Neurological Diseases
        • 5.4.3. Cancer
          • 5.4.3.1. Breast Cancer
          • 5.4.3.2. Lung Cancer
          • 5.4.3.3. Colorectal Cancer
          • 5.4.3.4. Melanoma
          • 5.4.3.5. Gastric Cancer
        • 5.4.4. Infectious Diseases
        • 5.4.5. Others
      • 5.5. Market Analysis, Insights and Forecast – By End User
        • 5.5.1. Pharmaceutical & Biopharmaceutical Companies
        • 5.5.2. Reference Laboratories
        • 5.5.3. CROs
        • 5.5.4. Others
      • 5.6. Market Analysis, Insights and Forecast – By Region
        • 5.6.1. North America
        • 5.6.2. Europe
        • 5.6.3. Asia Pacific
        • 5.6.4. Latin America, Middle East and Africa

      6. North America Companion Diagnostics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Product & Service
        • 6.2.1. Assay kits & Reagents
        • 6.2.2. Software & Services
      • 6.3. Market Analysis, Insights and Forecast – By Technology
        • 6.3.1. Polymerase Chain Reaction (PCR)
        • 6.3.2. In Situ Hybridization (ISH)
        • 6.3.3. Next-Generation Sequencing (NGS)
        • 6.3.4. Immunohistochemistry (IHC)
        • 6.3.5. Others
      • 6.4. Market Analysis, Insights and Forecast – By Indication
        • 6.4.1. Cardiovascular
        • 6.4.2. Neurological Diseases
        • 6.4.3. Cancer
          • 6.4.3.1. Breast Cancer
          • 6.4.3.2. Lung Cancer
          • 6.4.3.3. Colorectal Cancer
          • 6.4.3.4. Melanoma
          • 6.4.3.5. Gastric Cancer
        • 6.4.4. Infectious Diseases
        • 6.4.5. Others
      • 6.5. Market Analysis, Insights and Forecast – By End User
        • 6.5.1. Pharmaceutical & Biopharmaceutical Companies
        • 6.5.2. Reference Laboratories
        • 6.5.3. CROs
        • 6.5.4. Others
      • 6.6. Market Analysis, Insights and Forecast – By Country
        • 6.6.1. U.S.
        • 6.6.2. Canada

      7. Europe Companion Diagnostics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Product & Service
        • 7.2.1. Assay kits & Reagents
        • 7.2.2. Software & Services
      • 7.3. Market Analysis, Insights and Forecast – By Technology
        • 7.3.1. Polymerase Chain Reaction (PCR)
        • 7.3.2. In Situ Hybridization (ISH)
        • 7.3.3. Next-Generation Sequencing (NGS)
        • 7.3.4. Immunohistochemistry (IHC)
        • 7.3.5. Others
      • 7.4. Market Analysis, Insights and Forecast – By Indication
        • 7.4.1. Cardiovascular
        • 7.4.2. Neurological Diseases
        • 7.4.3. Cancer
          • 7.4.3.1. Breast Cancer
          • 7.4.3.2. Lung Cancer
          • 7.4.3.3. Colorectal Cancer
          • 7.4.3.4. Melanoma
          • 7.4.3.5. Gastric Cancer
        • 7.4.4. Infectious Diseases
        • 7.4.5. Others
      • 7.5. Market Analysis, Insights and Forecast – By End User
        • 7.5.1. Pharmaceutical & Biopharmaceutical Companies
        • 7.5.2. Reference Laboratories
        • 7.5.3. CROs
        • 7.5.4. Others
      • 7.6. Market Analysis, Insights and Forecast – By Country
        • 7.6.1. UK
        • 7.6.2. Germany
        • 7.6.3. France
        • 7.6.4. Italy
        • 7.6.5. Spain
        • 7.6.6. Russia
        • 7.6.7. Rest of Europe

      8. Asia Pacific Companion Diagnostics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Product & Service
        • 8.2.1. Assay kits & Reagents
        • 8.2.2. Software & Services
      • 8.3. Market Analysis, Insights and Forecast – By Technology
        • 8.3.1. Polymerase Chain Reaction (PCR)
        • 8.3.2. In Situ Hybridization (ISH)
        • 8.3.3. Next-Generation Sequencing (NGS)
        • 8.3.4. Immunohistochemistry (IHC)
        • 8.3.5. Others
      • 8.4. Market Analysis, Insights and Forecast – By Indication
        • 8.4.1. Cardiovascular
        • 8.4.2. Neurological Diseases
        • 8.4.3. Cancer
          • 8.4.3.1. Breast Cancer
          • 8.4.3.2. Lung Cancer
          • 8.4.3.3. Colorectal Cancer
          • 8.4.3.4. Melanoma
          • 8.4.3.5. Gastric Cancer
        • 8.4.4. Infectious Diseases
        • 8.4.5. Others
      • 8.5. Market Analysis, Insights and Forecast – By End User
        • 8.5.1. Pharmaceutical & Biopharmaceutical Companies
        • 8.5.2. Reference Laboratories
        • 8.5.3. CROs
        • 8.5.4. Others
      • 8.6. Market Analysis, Insights and Forecast – By Country
        • 8.6.1. China
        • 8.6.2. India
        • 8.6.3. Japan
        • 8.6.4. Australia
        • 8.6.5. South East Asia
        • 8.6.6. Rest of Asia Pacific

      9. Latin America, Middle East and Africa Companion Diagnostics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Product & Service
        • 9.2.1. Assay kits & Reagents
        • 9.2.2. Software & Services
      • 9.3. Market Analysis, Insights and Forecast – By Technology
        • 9.3.1. Polymerase Chain Reaction (PCR)
        • 9.3.2. In Situ Hybridization (ISH)
        • 9.3.3. Next-Generation Sequencing (NGS)
        • 9.3.4. Immunohistochemistry (IHC)
        • 9.3.5. Others
      • 9.4. Market Analysis, Insights and Forecast – By Indication
        • 9.4.1. Cardiovascular
        • 9.4.2. Neurological Diseases
        • 9.4.3. Cancer
          • 9.4.3.1. Breast Cancer
          • 9.4.3.2. Lung Cancer
          • 9.4.3.3. Colorectal Cancer
          • 9.4.3.4. Melanoma
          • 9.4.3.5. Gastric Cancer
        • 9.4.4. Infectious Diseases
        • 9.4.5. Others
      • 9.5. Market Analysis, Insights and Forecast – By End User
        • 9.5.1. Pharmaceutical & Biopharmaceutical Companies
        • 9.5.2. Reference Laboratories
        • 9.5.3. CROs
        • 9.5.4. Others
      • 9.6. Market Analysis, Insights and Forecast – By Country
        • 9.6.1. Brazil
        • 9.6.2. Saudi Arabia
        • 9.6.3. UAE
        • 9.6.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. F. Hoffmann-La Roche AG
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. Agilent Technologies, Inc.
      • 10.6. QIAGEN N.V.
      • 10.7. Abbott Laboratories, Inc.
      • 10.8. Almac Group
      • 10.9. Danaher Corporation
      • 10.10. Illumina, Inc.
      • 10.11. bioMérieux SA (France),
      • 10.12. Myriad Genetics, Inc.,
      • 10.13. Sysmex Corporation
      • 10.14. Thermo Fisher Scientific Inc.
      • 10.15. Abnova Corporation
      • 10.16. Guardant Health, Inc.
      • 10.17. Icon Plc
      List of Figures

      Figure 1: Global Companion Diagnostics Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Companion Diagnostics Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Companion Diagnostics Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Companion Diagnostics Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Companion Diagnostics Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Companion Diagnostics Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Companion Diagnostics Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Companion Diagnostics Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Companion Diagnostics Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Companion Diagnostics Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Companion Diagnostics Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Companion Diagnostics Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Companion Diagnostics Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Companion Diagnostics Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Companion Diagnostics Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Companion Diagnostics Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Companion Diagnostics Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Companion Diagnostics Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Companion Diagnostics Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Companion Diagnostics Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Companion Diagnostics Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Companion Diagnostics Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Companion Diagnostics Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Companion Diagnostics Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Companion Diagnostics Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Companion Diagnostics Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Companion Diagnostics Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Companion Diagnostics Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Companion Diagnostics Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Companion Diagnostics Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Companion Diagnostics Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Companion Diagnostics Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Companion Diagnostics Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Companion Diagnostics Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Companion Diagnostics Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Companion Diagnostics Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Companion Diagnostics Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Companion Diagnostics Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Companion Diagnostics Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Companion Diagnostics Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934